MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients
with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.